BenevolentAI Results Presentation Deck
2022: A year of solid progress and
growth for BenevolentAl
Enhanced the Benevolent Platform™, progressed our pipeline and delivered in
commercial collaboration with AstraZeneca
BEN-2293: Completed Phase Ila study and
expect top-line data in Q1 2023
BEN-8744: Submitted CTA in Dec 2022,
expect to initiate a Phase I clinical trial in H1
2023
BEN-28010: Declared as a clinical candidate
in July 2022, with preparation for
IND-enabling studies ongoing
3 year collaboration expansion with AstraZeneca's
into 2 new disease areas
3
3
4
new in-house drug programmes generated using
the Benevolent Platform™
FDA
BenevolentAl Proprietary
additional novel targets selected for
AstraZeneca's portfolio
in-house assets transitioned into lead
optimisation
approval of COVID-19 treatment (baricitinib)
first identified by BenevolentAl
Benevolent
4View entire presentation